The practical approach to neurogenic LUTD

Poster Session 52

Sunday, 13 March
15:45 - 17:15

Location: Room 14a (ICM, Level 1)

Chairs: T.M. Kessler, Zürich (CH)
A.M.M.S. Tayib, Jeddah (SA)
G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation
Overview of new approaches and longterm outcome in neurogenic patients.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

646

Effect of early sacral and pudendal neuromodulation on lower urinary tract and spinal cord in spinal cord injury mini pigs
By: Foditsch E.E. 1, Patras I. 2, Hutu I. 2, Bauer S. 1, Roider K. 1, Sievert K-D. 1, Zimmermann R. 1
Institutes: Paracelsus Medical University, Dept. of Urology and Andrology, Salzburg, Austria, 2 Banat University of Agricultural Sciences and Veterinary Medicine, Dept. of Animal Productions and Veterinary Public Health, Timisoara, Romania

647

Efficacy and safety of onabotulinumtoxinA 100U for treatment of urinary incontinence due to neurogenic detrusor overactivity in non-catheterising multiple sclerosis patients
By: Chartier-Kastler E. 1, Denys P. 2, Keppenne V. 3, Brucker B. 4, Egerdie B. 5, Magyar A. 6, Nicando J.P. 7, Jenkins B. 7, Kohan A. 8

648

Lower urinary tract dysfunction is the major concern of adult patients with spina bifida: Data from a prospective cohort of 371 patients
By: Peyronnet B. 1, Brochard C. 2, Jezquel M. 3, Ménard H. 3, Damphousse M. 4, Bonan I. 4, Kerdraon J. 4, Siproudhis L. 2, Gamé X. 5, Manunta A. 1
Institutes: CHU Rennes, Dept. of Urology, Rennes, France, 2 CHU Rennes, Dept. of Gastrology, Rennes, France, 3 CHU Rennes, Referral Center For Spina Bifida, Rennes, France, 4 CHU Rennes, Dept. of Physical Medicine, Rennes, France, 5 CHU Toulouse, Dept. of Urology, Toulouse, France

649

Bacteriuria in patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity: Do we need antibiotic prophyaxis?
By: Leitner L. 1, Sammer U. 2, Walter M. 2, Knüpf S. 2, Schneider M.P. 2, Seifert B. 4, Mehnert U. 2, Kessler T.M. 2
Institutes: Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology and Urology, Zürich and Basel, Switzerland, 2 Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, 3 ETH Zürich, Brain Research Institute, Zürich, Switzerland, 4 University of Zurich, Dept. of Biostatistics and Prevention, Zürich, Switzerland

651

Urodynamic findings in amiotrophic lateral sclerosis patients with lower urinary tract symptoms
By: Arlandis S. 1, Vazquez-Costa J.F. 2, Martinez-Cuenca E. 1, Sevilla T. 2, Boronat F. 1, Broseta E. 1
Institutes: Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain, 1 Hospital
Intradetrusor injections of onabotulinum toxin A (Botox®) 300 u or 200 u versus abobotulinum toxin A (Dysport®) 750 u in the management of neurogenic detrusor overactivity: A case control study

By: Peyronnet B. 1, Castel-Lacanal E. 2, Roumiguié M. 3, Even L. 3, Guillotreau J. 3, Marque P. 2, Soulé M. 3, Rischmann P. 1, Gamé X. 4

Institutes: CHU Rennes, Dept. of Urology, Rennes, France, 2CHU Toulouse, Dept. of Physical Medicine, Toulouse, France, 3CHU Toulouse, Dept. of Urology, Toulouse, France, 1CHU Toulouse, Dept. of Urology, Toulouse, France

Urinary and sexual dysfunction in patients affected by Parkinson's disease

By: Gubbiotti M. 1, Rossi De Vermandois J.A. 1, Boni A. 1, Proietti S. 2, Conte A. 3, Berardelli A. 3, Giannantoni A. 1

Institutes: University of Perugia, Dept. of Surgical and Biomedical Sciences, Perugia, Italy, 2Pierre and Marie Curie University, Tenon Hospital, Dept. of Urology, Paris, France, 3Sapienza University of Rome, Dept. of Neurology and Psychiatry, Rome, Italy

Is an early anticholinergic treatment able to prevent detrusor overactivity after spinal cord transection in rats?

By: Biardeau X., Aharony S., Loutochin O., Campeau L., Corcos J.

Institutes: Jewish General Hospital, Dept. of Urology, Montreal, Canada

Impairment of sensory nerves by onabotulinumtoxinA improves neurogenic detrusor overactivity following spinal cord injury

By: Coelho A. 1, Oliveira R. 2, Cruz F. 1, Cruz C. 2

Institutes: University of Porto, Dept. of Renal, Urologic and Infectious Diseases, Porto, Portugal, 2University of Porto, Dept. of Experimental Biology, Porto, Portugal

Mirabegron and refractory neurogenic urinary incontinence

By: Andretta E. 1, Virdone S. 2, Filocamo M.T. 3, Zuliani C. 4, Artuso G. 1

Institutes: General Hospital Ulss 13 Veneto, Dept. of Urology, Dolo, Italy, 2CRO National Cancer Institute, Dept. of Epidemiology, Aviano, Italy, 3General Hospital, Dept. of Urology, Savigliano, Italy, 4General Hospital Ulss 13 Veneto, Dept. of Neurology, Mirano, Italy

More than 15 years experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: Lessons to be learned

By: Tornic J. 1, Leitner L. 2, Guggenbühl S. 1, Walter M. 1, Knüpfel S. 1, Schneider M.P. 3, Mehnert U. 1, Kessler T.M. 1

Institutes: Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, 2Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology/Urology, Zürich and Basel, Switzerland, 3ETH Zürich, Brain Research Institute, Zürich, Switzerland

Risks factors for recurrent urinary tract infections in patients with multiple sclerosis

By: Phé V. 1, Curtis C. 2, Neha S. 1, Porter B. 3, Chataway J. 3, Panicker J. 1, Pakzad M. 1

Institutes: The National Hospital For Neurology and Neurosurgery, Dept. of Uro-Neurology and UCL Institute of Neurology, London, United Kingdom, 2University College London Hospital, Dept. of Microbiology, London, United Kingdom, 3The National Hospital For Neurology and Neurosurgery, Dept. of Neurology and UCL Institute of Neurology, London, United Kingdom

Pudendal nerve neuromodulation: Where do we stand? Trends after analysis of a ten year experience

By: Renard J.F.E. 1, Citeri M. 2, Zanollo L. 2, Guerrer C. 1, Rizzardi L. 2, Frediani L. 2, Iselin C. 1, Spinelli M. 2

Institutes: Hôpitaux Universitaires de Genève, Dept. of Urology, Genève, Switzerland, 2Niguarda Hospital, Spinal Unit, A. Zanollo Center for Sacral Area Dysfunctions, Milan, Italy

Summary and context

T.M. Kessler, Zürich (CH)